Evidence map›Paper›PMID 41751392›Full record

ArticleCurrent issues in molecular biology2026

Design, Synthesis, Analysis, and Cytotoxicity of Novel Heteroaryl Derivatives of Dipyridothiazines.

Emilia Martula, Paulina Strzyga-Łach, Marta Struga, Katarzyna Żurawska, Weronika Bagrowska, Anna Kasprzycka, Małgorzata Jeleń, Beata Morak-Młodawska

Abstract read
In one paragraph

Article in Current issues in molecular biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Emilia MartulaDoctoral School, The Medical University of Silesia, 40-055 Katowice, Poland.
Paulina Strzyga-ŁachDepartment of Biochemistry, Medical University of Warsaw, 02-097 Warsaw, Poland.ORCID 0000-0003-1830-2210
Marta StrugaDepartment of Biochemistry, Medical University of Warsaw, 02-097 Warsaw, Poland.ORCID 0000-0002-0181-3607
Katarzyna ŻurawskaBiotechnology Centre, The Silesian University of Technology, Krzywoustego Street 8, 44-100 Gliwice, Poland.ORCID 0000-0003-3023-6260
Weronika BagrowskaTunneling Group, Biotechnology Centre, The Silesian University of Technology, Krzywoustego 8, 44-100 Gliwice, Poland.ORCID 0000-0003-1749-8514
Anna KasprzyckaBiotechnology Centre, The Silesian University of Technology, Krzywoustego Street 8, 44-100 Gliwice, Poland.ORCID 0000-0002-9362-719X
Małgorzata JeleńDepartment of Organic Chemistry, Faculty of Pharmaceutical Sciences, The Medical University of Silesia, Jagiellońska 4, 41-200 Sosnowiec, Poland.ORCID 0000-0002-4144-990X
Beata Morak-MłodawskaDepartment of Organic Chemistry, Faculty of Pharmaceutical Sciences, The Medical University of Silesia, Jagiellońska 4, 41-200 Sosnowiec, Poland.ORCID 0000-0001-5389-1079

Funding

Medical University of Silesia BNW-2-051/K/4/Fthe Metropolitan Science Support Fund program RW/10/2025, PCTT/16/2025
6 · The paper itself

Abstract

Heterocyclic compounds have enormous pharmacological potential and therefore play a key role in the design of new drugs. Dipyridothiazines, both heterocyclic compounds and phenothiazine derivatives, exhibit promising anticancer, immunostimulatory, and antioxidant activities. The aim of this study was to design, synthesize, and evaluate the cytotoxicity of new 10-heteroaryl dipyridothiazines based on 2,7- and 3,6-diazaphenothiazine cores. The structural characterization of the new compounds was confirmed by spectroscopic methods. Cytotoxicity analysis was performed using the MTT assay against human keratinocytes (HaCaT) and two types of cancer cell lines: breast cancer (MDA-MB-231), lung carcer (A-549). The reference drugs used in the study were doxorubicin and cisplatin. The group of derivatives studied included active compounds as well as inactive derivatives. In order to explain differences in an activity level, molecular modelling supported by molecular dynamics was performed on histone deacetylase 6 (HDAC6), a known therapeutic target associated with oncogenic transformation and cancer metastasis. Molecular docking indicated that the derivative formed on the 2,7-diazaphenothiazine core is a more potent HDAC6 inhibitor, characterized by more stable binding and more favourable complex energy, despite minimal structural differences compared to the compound formed on the 3,6-diazaphenothiazine core. A preliminary SAR analysis was performed.

Indexed as

anticancer activitycytotoxicitydiazaphenothiazinesheterocycleshistone deacetylase 6 (HDAC6)molecular docking

Identifiers

PMID41751392
PMCPMC12940024

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.